{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=32&q=hormone+receptor-positive", "query": { "q": "hormone receptor-positive", "condition": "Breast Cancer", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=33&q=hormone+receptor-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=31&q=hormone+receptor-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T09:24:23.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03952325", "title": "Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tesetaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Odonate Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2019-07-09", "completion_date": "2021-06-23", "has_results": false, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 9, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952325" }, { "nct_id": "NCT01823835", "title": "A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-0810", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2014-12-29", "completion_date": "2020-03-13", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 8, "location_summary": "San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01823835" }, { "nct_id": "NCT00590785", "title": "Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Risk", "Breast Cancer", "Positive Nodes", "Cyclophosphamide", "Doxorubicin" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "tamoxifen", "type": "DRUG" }, { "name": "ciprofloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "1996-08-13", "completion_date": "2015-01-13", "has_results": false, "last_update_posted_date": "2017-08-25", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590785" }, { "nct_id": "NCT04059484", "title": "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Amcenestrant", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2019-10-22", "completion_date": "2025-01-02", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairway", "state": "Kansas" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04059484" }, { "nct_id": "NCT06525766", "title": "Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen-receptor-positive Breast Cancer", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-10-01", "completion_date": "2030-10-15", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06525766" }, { "nct_id": "NCT00907959", "title": "A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "BZL101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bionovo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2012-01", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2012-02-08", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00907959" }, { "nct_id": "NCT00498901", "title": "Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "goserelin", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "leuprolide acetate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2007-02", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2013-05-09", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498901" }, { "nct_id": "NCT06517212", "title": "Tirzepatide Weight Loss for MRD+ Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasms", "Breast Cancers" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-11-26", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06517212" }, { "nct_id": "NCT06572800", "title": "Tka Assay for CDK4/6i", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic HER2-Negative Breast Carcinoma" ], "interventions": [ { "name": "DiviTum-TKa", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2023-09-05", "completion_date": "2025-09-16", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 18, "location_summary": "Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more", "locations": [ { "city": "Derby", "state": "Connecticut" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Glastonbury", "state": "Connecticut" }, { "city": "Greenwich", "state": "Connecticut" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06572800" }, { "nct_id": "NCT07647042", "title": "A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 750, "start_date": "2026-03-31", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-17T09:24:23.242Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07647042" } ] }